MedWatch

Eargo faces delisting if it fails to provide Q3 report

US-based hearing aid manufacturer Eargo, which is the center of an investigation concerning potential reimbursement fraud, is now being threatened with delisting by New York stock exchange Nasdaq, as it has yet to file its third quarterly report.

Photo: Eargo / PR

Hearing aid manufacturer Eargo, which is spearheaded by the Dane Christian Gormsen, is once again in hot water.

This time, New York stock exchange Nasdaq has threatened to delist the company should it fail to file the missing third quarterly report for the period that ended on Sep. 30, Eargo reports in a press release.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs